丸美生物(603983.SH)：筹划发行H股股票并申请在香港联合交易所上市

Core Viewpoint - Mamei Biotechnology (603983.SH) plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its capital strength and overseas financing capabilities, aiming to accelerate its international business strategy [1] Group 1 - The company intends to issue H-shares to improve its overall competitiveness and support its internationalization strategy [1] - The issuance will consider the interests of existing shareholders and the conditions of domestic and international capital markets [1] - The timing and specifics of the issuance will be determined by the board of directors based on market conditions and regulatory approvals within a 24-month period following the shareholders' meeting resolution [1]